Computational Design of Macrocyclic Peptides Containing Non-Natural Amino Acids

Join us for the NYAGIM 2025 Q3 event, supported by Cresset and the New York Academy of Sciences, featuring Dan Sindhikara on recent advances and persistent challenges in the computational design of macrocyclic peptides.

Abstract
In the wake of blockbuster GLP-1 inhibitors such as semaglutide and smaller, orally bioavailable peptides such as Merck's PCSK9 inhibitor, "MK-0616", attention to peptides as therapeutics continues to wax. Computational methods are following suit, but they generally require significant adaptation to be effective at delivering impact to peptide discovery projects. Today, I'll show how we adapt, develop, and apply physics-based, ML, and informatics to accelerate macrocyclic peptide design.

Event Details
Join the NYAGIM community to connect with peers from academia and industry working in in silico drug discovery. This is a great opportunity to exchange ideas, learn from leading experts, and be inspired.

• Format: In-person only (no remote attendance or recordings)
• RSVP Deadline: September 12, 2025

We look forward to seeing you there!